Impax Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
RBC Capital Cuts Price Target on Impax Laboratories (IPXL) Following Unexpected 2Q Miss
August 10, 2016 7:39 AM EDTRBC Capital maintained a Sector Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $30.00 (from $35.00), following the company's 2Q earnings report. RBC updated IPXL's model with new 2016-18 EPS estimates of $1.58, $2.24 and $2.46.
Analyst Randall Stanicky commented,... More
Impax Laboratories (IPXL) PT Cut to $24 at Leerink Partners
August 10, 2016 7:08 AM EDTLeerink Partners analyst Jason Gerberry cut his price target on Impax Laboratories (NASDAQ: IPXL) to $24.00 (from $33.00) following a big Q2 miss and "questionable" guidance. The firm maintained a Market Perform rating.
Gerberry commented, "In 2Q, IPXL missed consensus sales and EPS by 25% and 54%, respectively.... More
Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower
August 9, 2016 7:05 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.21, $0.11 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $173 million versus the consensus estimate of $223.67 million.
"Our second quarter results reflect the unexpected and rapid decline in sales of diclofenac and metaxalone as a result of additional competition," said Fred Wilkinson, President and Chief Executive Officer of Impax. "In particular, the change in the diclofenac market quickly moved us from an exclusive supplier position to a five competitor... More
